Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $315.4 million.

  • Axsome Therapeutics' Cash & Equivalents fell 0.62% to $325.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.3 million, marking a year-over-year decrease of 0.62%. This contributed to the annual value of $315.4 million for FY2024, which is 18.34% down from last year.
  • Axsome Therapeutics' Cash & Equivalents amounted to $315.4 million in FY2024, which was down 18.34% from $386.2 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Cash & Equivalents registered a high of $386.2 million during FY2023, and its lowest value of $200.8 million during FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Cash & Equivalents value was $315.4 million (recorded in 2024), while the average stood at $300.8 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Cash & Equivalents soared by 92.29% in 2023, and later decreased by 18.34% in 2024.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Cash & Equivalents stood at $200.8 million in 2022, then skyrocketed by 92.29% to $386.2 million in 2023, then decreased by 18.34% to $315.4 million in 2024.